

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Ribo Life Science Co., Ltd.

蘇州瑞博生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6938)

POSITIVE FINANCIAL INFORMATION ALERT

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the information currently available to the Board and the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 (the “**Reporting Period**”), the Group is expected to record revenue ranging between approximately RMB311 million and RMB436 million during the Reporting Period, representing an increase of approximately 200% to 320% over the same period in 2025, primarily attributable to the partial recognition of licensing revenue under the Group’s global exclusive licensing collaboration with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), together with the revenue recognized upon the achievement of milestones under the Group’s collaboration with Boehringer Ingelheim International GMBH, in relation to the development and commercialization of small interfering RNA (siRNA) therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), which constituted the primary driver of the Group’s revenue growth during the Reporting Period.

The information contained in this announcement is based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 and has not been reviewed by the auditor of the Company or the audit committee of the Board, which is subject to finalization and adjustments. Detailed financial information of the Group will be disclosed in the Company’s interim results announcement for the six months ended June 30, 2026, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, July 29, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.